{
    "clinical_study": {
        "@rank": "62089", 
        "arm_group": [
            {
                "arm_group_label": "SB2", 
                "arm_group_type": "Experimental", 
                "description": "SB2 (Study drug)"
            }, 
            {
                "arm_group_label": "EU Remicade", 
                "arm_group_type": "Active Comparator", 
                "description": "EU sourced Remicade (Reference drug)"
            }, 
            {
                "arm_group_label": "US Remicade", 
                "arm_group_type": "Active Comparator", 
                "description": "US sourced Remicade (Reference drug)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacokinetics, safety, tolerability and\n      immunogenicity of SB2 and Remicade (EU sourced Remicade and US sourced Remicade) in healthy\n      subjects."
        }, 
        "brief_title": "Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy female subjects of non-childbearing potential and healthy male subjects\n\n          -  Have a body weight between 60.0 and 94.9 kg and a body mass index between 20.0 and\n             29.9 kg/m\u00b2, inclusive.\n\n        Exclusion Criteria:\n\n          -  history and/or current presence of clinical significant atopic allergy,\n             hypersensitivity or allergic reactions, also including known or suspected clinically\n             relevant drug hypersensitivity to any components of the test and reference IP\n             formulation or comparable drugs.\n\n          -  active or latent Tuberculosis or who have a history of Tuberculosis.\n\n          -  history of invasive systemic fungal infections or other opportunistic infections\n\n          -  systemic or local infection, a known risk for developing sepsis and/or known active\n             inflammatory process\n\n          -  serious infection associated with hospitalisation and/or which required intravenous\n             antibiotics\n\n          -  history of and/or current cardiac disease\n\n          -  have received live vaccine(s) within 30 days prior to Screening or who will require\n             live vaccine(s) between Screening and the final study visit.\n\n          -  Intake medication with a half-life > 24 h within 1 month or 10 half-lives of the\n             medication prior to the administration of investigational product."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "159", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922336", 
            "org_study_id": "SB2-G11-NHV", 
            "secondary_id": "2012-005306-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "SB2", 
                "description": "IV infusion", 
                "intervention_name": "SB2", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "EU Remicade", 
                "description": "IV infusion", 
                "intervention_name": "EU Remicade", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "US Remicade", 
                "description": "IV infusion", 
                "intervention_name": "US Remicade", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Infliximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacokinetics", 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "Parexel International GmbH"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Infliximab (SB2, EU Sourced Remicade\u00ae and US Sourced Remicade\u00ae) in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Parexel International GmbH", 
            "last_name": "Rainard Fuhr, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve from time zero to infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "71 days"
            }, 
            {
                "measure": "Maximum serum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "71 days"
            }, 
            {
                "measure": "Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "71 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Time to Cmax (Tmax)", 
            "safety_issue": "No", 
            "time_frame": "71 days"
        }, 
        "source": "Samsung Bioepis Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Bioepis Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}